WHO and AZ Vaccine (CG)▶ Click here for a larger view
Vaccine experts of the World Health Organization (WHO) positively evaluated the novel coronavirus infection (Corona 19) vaccine developed by AstraZeneca on the 19th (local time).
The COVID-19 subcommittee of the WHO Vaccine Safety Advisory Committee (GACVS) said in a statement that the AstraZeneca vaccine continues to receive positive reviews in a benefit-risk profile. It has tremendous potential to reduce.”
The subcommittee said, “The available data do not suggest an overall increase in thrombotic diseases such as deep venous thrombosis or pulmonary embolism after COVID-19 vaccine administration.”
“The incidence of thromboembolic events reported after the COVID-19 vaccination is close to the expected number of diagnoses for these diseases,” he said. “Both diseases occur naturally and are not uncommon.”
In particular, he pointed out that “a very rare and special thromboembolic disease in combination with thrombocytopenia such as cerebral venous sinus thrombosis has been reported in Europe after AstraZeneca’s COVID-19 vaccination, but it is unclear whether it is due to vaccination.” .
The subcommittee urged countries to continue to monitor the safety of all COVID-19 vaccines and report any suspected abnormalities.
“We agree with the plan for the European Medicines Agency (EMA) to further investigate and monitor these phenomena.”
“We understand that people may have been concerned about the safety of the AstraZeneca vaccine,” said WHO Secretary General Thewardros Adhanom Gobrersuss at a video press briefing held today. The question is whether the risk of accepting it is greater or less than the risk of the disease.”
“There is no doubt in this case,” he said. “Corona 19 is a deadly disease and the AstraZeneca vaccine can prevent it.”
“It is important to remember that Corona 19 itself can cause platelet reduction and blood clots,” he said. “We urge countries to continue using this important vaccine.”
“The AstraZeneca vaccine is particularly important because it accounts for more than 90% of the vaccine distributed through CoVax (an international project for joint purchase and distribution of Corona 19 vaccine).”
In addition, he re-emphasized the importance of an equitable vaccine, saying that the number of corona19 confirmed cases around the world is increasing for 4 consecutive weeks.
He said he will meet with the secretary-general of the World Trade Organization (WTO) next week to discuss ways to increase vaccine production.
Meanwhile, WHO officials announced that they will conclude next month whether to approve the urgent use of vaccines produced by China’s Sinopam and Sinobac, and that they are waiting for sufficient data submission on the Russian Sputnik V vaccine.
[연합뉴스]
Copyrights ⓒ Yonhap News. Unauthorized reproduction and redistribution prohibited